

Wilson Disease

Diagnosis

Indications for Testing

- Unexplained liver disease in patients <40 years of age
- Unexplained neurological disease, especially in concert with liver disease
- Kayser-Fleischer rings on ophthalmic exam
- Family history of the disease in first-degree relative

Laboratory Testing

- Pattern of results consistent with Wilson disease is most useful for diagnosis
 - Ceruloplasmin – decreased (<200 mg/L is highly suggestive of disease)
 - Serum free copper – increased (>10 µg/dL is suggestive)
 - Urine (24 hour) copper – increased (>100 µg/24-hours is considered diagnostic)
 - Hepatic function – transaminases may be elevated; however, not useful in diagnosis
 - Molecular testing – *ATP7B* mutation
 - Not recommended in patient's children; close monitoring may be indicated

Histology

- Liver biopsy – increased copper concentrations (>250mg/g dry weight is diagnostic)
 - Copper content may be less in cirrhotic liver because of uneven distribution of copper in parenchyma

Imaging Studies

- MRI is most useful – increased signal intensity in the basal ganglia on T2 weighted images

Differential Diagnosis

- Hepatic manifestations
 - Viral hepatitis – hepatitis A, B, C or D
 - Chronic hepatitis – hepatitis B or C, autoimmune hepatitis
 - Chronic cholestasis – primary sclerosing cholangitis, primary biliary cirrhosis
- Neurologic manifestations
 - Degenerative cerebellar or metabolic diseases
 - Demyelinating disease – amyotrophic lateral sclerosis (ALS)
 - Metabolic storage disease – Gaucher disease
 - Vasculitis – microscopic polyangiitis, Churg-Strauss syndrome, polyarteritis nodosa
 - Central nervous system infections – viral, bacterial, parasitic, fungal
 - Seizure disorder
 - Parkinsons disease
 - Transverse myelitis
 - Familial chorea
 - Early onset Huntington disease
- Psychiatric
 - Psychoses
 - Depression
 - Schizophrenia
 - Drug abuse

Screening

- Genetic testing – consider screening for ATPase (*ATP7B*) genetic mutation

- Negative result does not exclude Wilson disease

Monitoring

- If Kayser-Fleischer rings are initially present, rings should break up and disappear with therapy
- Measuring serum free copper is useful in monitoring therapy effectiveness
 - Aims to reduce into normal concentrations

Clinical Background

Wilson disease (also called hepatolenticular degeneration, Westphal-Struempell disease, and Westphal pseudosclerosis) is an autosomal recessive inherited disorder of [copper](#) metabolism.

Epidemiology

- Incidence – 1/30,000
- Age – onset of symptoms <40 years
- Sex – M:F, equal

Inheritance

- Caused by mutation in the *ATP7B* gene (located on chromosome 13)
- Autosomal recessive transmission
 - ~1% of population are carriers

Pathophysiology

- Ceruloplasmin, a late [acute phase reactant](#), is the principal copper-containing protein of plasma and is transported into the trans-Golgi network of all cells by copper-transporting ATPases
- Disease results from the absence or dysfunction of copper-transporting ATPases
- Variant P-type ATPase prevents incorporation of copper into ceruloplasmin, resulting in elevated concentrations of circulating free copper
- Excess copper is deposited in the kidneys, liver (causes [cirrhosis](#)), eyes (manifests as Kayser-Fleischer rings) and brain (damages the basal ganglia)
- Other conditions that prevent the elimination of copper (eg, biliary obstruction) may also lead to elevated free copper concentrations

Clinical Presentation

- Ophthalmic manifestations
 - Kayser-Fleischer rings (copper deposit on corneal Descemet membrane)
 - Seen in 50-60% of patients
 - Not specific for Wilson disease – can also be seen in chronic cholestasis
 - Presence does not correlate with severity
- Hepatic manifestations – hepatomegaly, fatty liver, [hepatitis](#), cirrhosis
- Neurologic manifestations – movement disorders
 - Typically develop in the 20s and affect 40-50% of patients
 - Dystonia, tremor, incoordination, rigidity, hypomimia
 - Bulbar and pseudobulbar palsies with hypokinetic speech and dysphagia
- Psychiatric manifestations
 - Behavioral disturbances, depression, hallucinations, paranoia
 - Frequently occur prior to hepatic and neurologic symptoms
- Complications
 - Hematologic – [hemolytic anemia](#), thrombocytopenia
 - Musculoskeletal – [arthritis](#), [osteoporosis](#)

- Renal – nephrolithiasis, aminoaciduria, Fanconi syndrome
- Cardiac – cardiomyopathy, arrhythmias
- Endocrine – hypoparathyroidism, infertility
- Other – gall stones, pancreatitis

Treatment

- Goal of therapy is to reduce copper accumulation; prompt diagnosis is crucial because treatment requires 3-6 months for the desired effect
- Untreated Wilson disease can be fatal – result of fulminant liver failure and/or brain damage

Lab Tests

Indications for Laboratory Testing

Tests generally appear in the order most useful for common clinical situations. For test-specific information, refer to the test number in the ARUP Laboratory Test Directory on the ARUP Web site at www.aruplab.com.

Test Name and Number	Recommended Use	Limitations	Follow Up
Wilson Disease Screening Panel, Serum 0020598 Method: Quantitative Immunoturbidimetry/ Quantitative Inductively Coupled Plasma-Mass Spectrometry	Diagnose conditions of copper overload in symptomatic patients or patients with a family history of Wilson disease Panel includes serum ceruloplasmin, serum copper and free serum copper Supports diagnosis of Wilson disease and monitors therapy in patient with Wilson disease	See individual component tests Ceruloplasmin false positives may reflect malabsorption, aceruloplasminemia, liver insufficiency, heterozygotes for Wilson disease, inflammatory conditions	
Copper, Urine 0020461 Method: Quantitative Inductively Coupled Plasma-Mass Spectrometry	Supportive test in diagnosis of Wilson disease	False positives from hepatocellular necrosis	
Copper, Liver 0020694 Method: Quantitative Inductively Coupled Plasma-Mass Spectrometry	Supportive test in diagnosis of Wilson disease	False positives from alcoholic hepatitis, cholestatic syndromes	

<p>Copper, Serum Free (Direct) 0020596 Method: Quantitative Inductively Coupled Plasma-Mass Spectrometry</p>	<p>Supportive test in diagnosis of Wilson disease Monitoring therapy in patient with Wilson disease</p>	<p>Performed with serum ultrafiltrates Elevated in Wilson disease or other conditions of copper overload Elevated results should be confirmed with a second specimen to exclude the possibility of external contamination</p>	
<p>Ceruloplasmin 0050160 Method: Quantitative Immunoturbidimetry</p>	<p>Supportive test in diagnosis of Wilson disease</p>	<p>Positive result may not necessarily indicate Wilson disease because decreased ceruloplasmin levels may also be found in inflammatory conditions Pregnancy and oral contraceptives increase ceruloplasmin levels Low ceruloplasmin levels also found in malnutrition, malabsorption, nephrosis, severe liver disease</p>	

Hepatic Function Panel 0020416	Supportive test in diagnosis of hepatic dysfunction		
Method: Quantitative Enzymatic/Quantitative Spectrophotometry	Panel includes albumin; alkaline phosphatase; aspartate aminotransferase; alanine aminotransferase; bilirubin, direct; protein, total; bilirubin, total		

Additional Tests Available

Test Name and Number	Comments
Copper, Serum 0020096	Test available alone or as part of Wilson disease serum screening panel that also includes serum ceruloplasmin and serum free copper
Method: Quantitative Inductively Coupled Plasma-Mass Spectrometry	False positives from infection, inflammation, stress, copper supplementation, oral contraceptives, pregnancy Pregnancy – concentrations are 2-3 times normal in third trimester Copper may be lowered by corticosteroids, zinc, malnutrition, malabsorption

Guidelines

Diagnosis and treatment of Wilson disease: an update. American Association for the Study of Liver Diseases - Private Nonprofit Research Organization. 2003 June (Revised 2008 June).
 Roberts EA, Schilsky ML. A practice guideline on Wilson disease. *Hepatology*. 2003; 37 (6) :1475-1492.

General References

Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. *Lancet*. 2007; 369 (9559) :397-408.
 Ferenci P. Wilson's Disease. *Clin Gastroenterol Hepatol*. 2005; 3 (8) :726-733.
 Gouider-Khouja N. Wilson's disease. *Parkinsonism Relat Disord*. 2009; 15 Suppl 3 :S126-S129.
 Huster D. Wilson disease. *Best Pract Res Clin Gastroenterol*. 2010; 24 (5) :531-539.
 Lorincz MT. Neurologic Wilson's disease. *Ann N Y Acad Sci*. 2010; 1184 :173-187.
 Mak CM, Lam CW. Diagnosis of Wilson's disease: a comprehensive review. *Crit Rev Clin Lab Sci*. 2008; 45 (3) :263-290.
 McMillin GA, Travis JJ, Hunt JW. Direct measurement of free copper in serum or plasma ultrafiltrate. *Am J Clin Pathol*. 2009; 131 (2) :160-165.
 Medici V, Rossaro L, Sturniolo GC. Wilson disease--a practical approach to diagnosis, treatment and follow-up. *Dig Liver Dis*. 2007; 39 (7) :601-609.
 Pfeiffer RF. Wilson's Disease. *Semin Neurol*. 2007; 27 (2) :123-132.
 Walshe JM. Monitoring copper in Wilson's disease. *Adv Clin Chem*. 2010; 50 :151-163.

References from the ARUP Institute for Clinical and Experimental Pathology®

McMillin GA, Travis JJ, Hunt JW. Direct measurement of free copper in serum or plasma ultrafiltrate. *Am J Clin Pathol*. 2009; 131 (2) :160-165.

Reviewed by

McMillin, Gwendolyn A., PhD. Medical Director of Toxicology and Trace Elements, Co-Medical Director of Pharmacogenomics at ARUP Laboratories; Associate Professor of Pathology (Clinical), University of Utah

Diagnostic Algorithm(s)

PDF algorithm(s) available at www.arupconsult.com.

Wilson Disease Testing Algorithm

Related Content

Alpha-1-Antitrypsin Deficiency - AAT

Cirrhosis

Hemochromatosis

Hepatitis B Virus - HBV

Hepatitis C Virus - HCV

Hepatitis, Autoimmune - AIH

Hepatocellular Carcinoma

Liver Disease Evaluation

Comprehensive Review: December 2011

Last Update: December 2011